… Chimeric antigen receptor (CAR) T cell therapy of cancer is generating enormous
enthusiasm. Twenty-five years after the concept was first proposed, major advances in molecular …

… Chimeric antigen receptor (CAR)-T-cell therapy is a promising approach for the treatment
of refractory malignancies, but is associated with unique acute toxicities that need specialized …

… that are resistant to standard therapies. Indeed, unresponsiveness to … -cell transplantation
are indicators of an especially poor prognosis. Chimeric antigen receptor (CAR) T cells are …

… two CD19-targeted chimeric antigen receptor (CAR) T cell therapies: … These therapies have
remarkable efficacy in some blood … Pioneering CAR T cell therapies CAR T cell therapies are …

… So far, roughly 30 solid tumor antigens are being evaluated for CAR T-cell therapy; these …
antigens, tumor-selective antigens (ie, enriched expression of antigens on neoplastic cells, but …

… Chimeric antigen receptor (CAR) T cells directed against the B-cell marker CD19 are … and/or
relapsed B-cell malignancies. Due to the nature of CAR T cells as living drugs, they display …

… efforts to develop CAR T-cell therapy beyond B-cell malignancies. In this review, we explain
the concept of chimeric antigen receptor gene-modified T cells, describe the extant results in …

… In this study, we review the principles underlying CAR T cell therapy, discuss obstacles to
further improve results in hematologic cancers, and extend this approach to common cancers …

… The present report describes the current status of chimeric antigen receptor (CAR) T … B-cell
malignancies. CAR T cells targeting CD19, a protein expressed on many B-cell malignancies, …

… therapeutic benefit of adoptive T-cell therapy against glioblastoma with the use of CAR-engineered
T cells targeting IL13Rα2, a glioma-associated antigen … CAR T-cell therapy has been …